EU/3/20/2305: Orphan designation for the treatment of myelodysplastic syndromes
Imetelstat sodium
Table of contents
Overview
On 27 July 2020, orphan designation EU/3/20/2305 was granted by the European Commission to Parexel International GmbH, Germany, for imetelstat sodium for the treatment of myelodysplastic syndromes.
Key facts
Active substance |
Imetelstat sodium
|
Intended use |
Treatment of myelodysplastic syndromes
|
Orphan designation status |
Positive
|
EU designation number |
EU/3/20/2305
|
Date of designation |
27/07/2020
|
Sponsor |
Geron Netherlands B.V. |
Review of designation
The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.
Update history
Date | Update |
---|---|
June 2023 | The sponsorship was transferred to Geron Netherlands B.V., Netherlands in June 2023. |
Patients' organisations
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: